<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820558</url>
  </required_header>
  <id_info>
    <org_study_id>VanilloidGenetics-001-13</org_study_id>
    <nct_id>NCT02820558</nct_id>
  </id_info>
  <brief_title>Neuropeptide Therapy of Recent Onset Type 1 Diabetes</brief_title>
  <official_title>A Phase I Study of Safety and Pharmacological Activity of Substance P (sP) in the Reversal of Recent-Onset Type 1 Diabetes (T1D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanilloid Genetics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanilloid Genetics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the delivery of substance P via the celiac artery in the treatment of
      recent onset type 1 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage A Safety: Side effects reported for entire cohort</measure>
    <time_frame>Reported during the first 20-27 days following sP administration</time_frame>
    <description>To determine if there are unexpected adverse events with intra arterial delivery of sP into the celiac artery in individuals with Type 1 Diabetes, and evidence of residual beta cell function as reflected by a peak C--‐peptide levels of &gt; 200 pmol/L. Multiple measurements per patient will be aggregated to arrive at one reported value: Number of participants with abnormal laboratory values, adverse events and/or peak C-peptide levels &gt;200pmol/L that are related to treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-Peptide Levels (small cohort)</measure>
    <time_frame>Day 20-27 post sP injection</time_frame>
    <description>To determine in an initial small cohort (n=12, toxicity and dose finding cohort) if one or more sP doses significantly increases the basal or stimulated c--‐Peptide levels at Day 20--‐27 post--‐injection using data from Mixed Meal Tolerance Test (MMTT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Peptide Levels (large cohort)</measure>
    <time_frame>Day 20-27 post sP injection</time_frame>
    <description>To assess in a larger cohort (n=40, continued safety and efficacy) whether sP dose, determined from the dose finding cohort, significantly increases basal or stimulated C-- peptide levels at Day 20--‐27 post sP--‐injection using MMTT data.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>sP Longevity</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>To determine an estimate of sP longevity in the entire cohort of patients, by monitoring HbA1c values, exogenous insulin requirement, daily recorded blood sugar levels and adverse event recording at 3 and 6 months post injection of sP. Multiple measurements per patient will be aggregated to arrive at one reported value for the aforementioned outcome measures.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Substance P - 1nmol/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Substance P 1nmol/kg intra-celiac artery, single treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substance P - 5nmol/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Substance P 5nmol/kg intra-celiac artery, single treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substance P - 15nmol/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Substance P 15nmol/kg intra-celiac artery, single treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substance P - 45nmol/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Substance P 45nmol/kg intra-celiac artery, single treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Substance P</intervention_name>
    <arm_group_label>Substance P - 1nmol/kg</arm_group_label>
    <arm_group_label>Substance P - 5nmol/kg</arm_group_label>
    <arm_group_label>Substance P - 15nmol/kg</arm_group_label>
    <arm_group_label>Substance P - 45nmol/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recent onset T1D (CDA 2013 guidelines: See link in links section

          -  Age 10-18 years

          -  Disease Duration 3-30 months

          -  Fasting C-Peptide (measured at screening) greater than or equal to 33 pmol/L

          -  Post honeymoon phase based on the following criteria: History of HbA1c values and
             insulin requirements from diagnosis indicating a honeymoon period followed by
             increased insulin requirements which at time of recruitment are &gt; 0.50 units/Kg
             together with an HbA1c value &gt; 7.2 %; Patients with diabetes duration &gt; 3 months who
             never experienced a honeymoon period as reflected by consistent HbA1c values &gt; 7.2 %
             from the time of diagnosis and at the time of recruitment are using an insulin dose &gt;
             0.50 units/Kg.

          -  The presence of one or more of the TRPV1 alleles similar to those found in patients
             currently enrolled in the TRPV1-North American - European Study.

          -  Stimulated C-Peptide (measured at mixed meal tolerance at Stage A and Stage B of sP
             trial) ≥ 200 pmol/L and less than or equal to 1500 pmol/L.

        Exclusion Criteria:

          -  Patients with known co-morbidities, including ACE-inhibitor treated hypertension as
             well as chromosomal abnormalities, involving one or more organ systems.

          -  Type 2 Diabetes Mellitus

          -  Patients with a known radiographic contrast allergy

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Etienne Sochett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Sick Children, Toronto Ontario</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holly Tschirhart</last_name>
    <phone>416-813-7654</phone>
    <phone_ext>204517</phone_ext>
    <email>holly.tschirhart@sickkids.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Pastor</last_name>
    <phone>416-813-7654</phone>
    <phone_ext>204396</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Tschirhart</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>204517</phone_ext>
      <email>holly.tschirhart@sickkids.ca</email>
    </contact>
    <contact_backup>
      <last_name>Catherine Pastor</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>204396</phone_ext>
      <email>catherine.pastor@sickkids.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://guidelines.diabetes.ca/Browse/Chapter3</url>
    <description>CDA 2013 guidelines</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <last_update_submitted>June 28, 2016</last_update_submitted>
  <last_update_submitted_qc>June 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuropeptide</keyword>
  <keyword>Therapy</keyword>
  <keyword>Onset</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance P</mesh_term>
    <mesh_term>Neurokinin A</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

